Compare · ACST vs HOOK
ACST vs HOOK
Side-by-side comparison of Acasti Pharma Inc. (ACST) and HOOKIPA Pharma Inc. (HOOK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACST and HOOK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ACST is the larger of the two at $49.6M, about 1.2x HOOK ($41.0M).
- HOOK has more recent analyst coverage (11 ratings vs 2 for ACST).
- Company
- Acasti Pharma Inc.
- HOOKIPA Pharma Inc.
- Price
- $3.59+9.79%
- $0.87-3.61%
- Market cap
- $49.6M
- $41.0M
- 1M return
- -
- +0.00%
- 1Y return
- -
- -8.41%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 0
- 0
- Recent ratings
- 2
- 11
Acasti Pharma Inc.
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.
HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Latest ACST
- Grace Therapeutics to Participate in Upcoming Investor Events January 2025
- Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference
- Acasti Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Acasti Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.
- SEC Form EFFECT filed by Acasti Pharma Inc.
- SEC Form EFFECT filed by Acasti Pharma Inc.
- SEC Form S-8 filed by Acasti Pharma Inc.
- SEC Form S-8 POS filed by Acasti Pharma Inc.
- SEC Form S-8 POS filed by Acasti Pharma Inc.
Latest HOOK
- HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
- HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
- HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
- Chief Executive Officer Peters Malte sold $20,684 worth of shares (25,172 units at $0.82), decreasing direct ownership by 32% to 54,347 units (SEC Form 4)
- SEC Form 15-12G filed by HOOKIPA Pharma Inc.
- SEC Form EFFECT filed by HOOKIPA Pharma Inc.
- SEC Form EFFECT filed by HOOKIPA Pharma Inc.
- SEC Form 25 filed by HOOKIPA Pharma Inc.
- SEC Form S-8 POS filed by HOOKIPA Pharma Inc.
- SEC Form S-8 POS filed by HOOKIPA Pharma Inc.